Finding 1215449 (2025-003)

Material Weakness Repeat Finding
Requirement
I
Questioned Costs
-
Year
2025
Accepted
2026-05-22
Audit: 402060
Organization: New York Blood Center, Inc. (NY)

AI Summary

  • Core Issue: A significant deficiency in internal controls was found regarding procurement practices, specifically related to not retaining price quotes for a purchase over $10,000.
  • Impacted Requirements: The organization did not comply with 2 CFR Section 200.320(a)(2), which mandates obtaining and retaining price quotations from qualified sources for simplified acquisitions.
  • Recommended Follow-Up: Ensure all procurement methods are properly documented and compliant for purchases exceeding the micro-purchase threshold of $10,000.

Finding Text

Federal Agency: U.S. Department of Health and Human Services Federal Program Title: Blood Diseases and Resources Research Assistance Listing Number: 93.839 Award Period: 3/1/2022 – 12/31/2028 Type of Finding: - Significant Deficiency in Internal Control over Compliance and Other Matters Criteria or specific requirement: 2 CFR Section 200.320(a)(2) states that when simplified acquisition procedures are used, price or rate quotations must be obtained from an adequate number of qualified sources. Condition: During our testing of procurement, we noted that the organization has a process to review quotes from more than one vendor before entering into a transaction with a vendor. However, we noted one instance of the simplified acquisition procurement method being used with no price or rate quotations obtained from qualified sources retained on file prior to the transaction being entered. Questioned costs: $11,868.60 Context: We noted 1 of the 5 tested purchases was acquired using the simplified acquisition procurement method being used with no price or rate quotations obtained from qualified sources. Cause: Per discussion with management, The Organization did obtain price or rate quotations from more than one qualified source for a purchase made using the simplified acquisition procurement method. However, the documentation was not retained to provide evidence that this took place before entering into a transaction with that vendor. Effect: $11,868.60 purchase with no justification for procurement method chosen. Repeat finding: No Recommendation: We recommend that the Organization follows all procurement method requirements for purchases over the $10,000 micro-purchase threshold. Views of responsible officials: There is no disagreement with the audit finding.

Corrective Action Plan

Blood Diseases and Resources Research (ALN 93.839) Recommendation: We recommend that the Organization follows all procurement method requirements for purchases over the $10k micro-purchase threshold. Explanation of disagreement with audit finding: There is no disagreement with the audit finding. Action taken in response to finding: Management has implemented procedure enhancements to its retainment and processing of documentation for simplified acquisition procedures. Including: quotes and other qualified sources documentation is attached to the relevant purchase requisition within our ERP system prior to submission of the requisition for review and approval; a three-step/tiered review and approval process. Name of the contact person responsible for corrective action: Mahtab Khan Planned completion date for corrective action plan: May 2026

Categories

Procurement, Suspension & Debarment

Other Findings in this Audit

  • 1215431 2025-001
    Material Weakness Repeat
  • 1215432 2025-001
    Material Weakness Repeat
  • 1215433 2025-001
    Material Weakness Repeat
  • 1215434 2025-001
    Material Weakness Repeat
  • 1215435 2025-001
    Material Weakness Repeat
  • 1215436 2025-001
    Material Weakness Repeat
  • 1215437 2025-001
    Material Weakness Repeat
  • 1215438 2025-001
    Material Weakness Repeat
  • 1215439 2025-001
    Material Weakness Repeat
  • 1215440 2025-002
    Material Weakness Repeat
  • 1215441 2025-003
    Material Weakness Repeat
  • 1215442 2025-003
    Material Weakness Repeat
  • 1215443 2025-003
    Material Weakness Repeat
  • 1215444 2025-003
    Material Weakness Repeat
  • 1215445 2025-003
    Material Weakness Repeat
  • 1215446 2025-003
    Material Weakness Repeat
  • 1215447 2025-003
    Material Weakness Repeat
  • 1215448 2025-003
    Material Weakness Repeat

Programs in Audit

ALN Program Name Expenditures
93.847 DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH $153,034
93.839 BLOOD DISEASES AND RESOURCES RESEARCH $105,563
93.242 MENTAL HEALTH RESEARCH GRANTS $80,417
93.103 FOOD AND DRUG ADMINISTRATION RESEARCH $77,426
93.867 VISION RESEARCH $58,498
93.368 21ST CENTURY CURES ACT - PRECISION MEDICINE INITIATIVE $17,454
93.855 ALLERGY AND INFECTIOUS DISEASES RESEARCH $1